Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...
Also Read: Regeneron’s Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market The condition ...
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...
Shares of Regeneron Pharmaceuticals Inc. REGN inched 0.07% higher to $829.43 Tuesday, on what proved to be an all-around ...
Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $1,000 from $1,150 and keeps an Outperform rating on the ...
Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...
11d
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its target price decreased by Royal Bank of Canada from ...
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an ...
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...
On Thursday, Regeneron Pharmaceuticals Inc (REGN) stock saw a decline, ending the day at $838.2 which represents a decrease of $-84.59 or -9.17% from the prior close of $922.79. The stock opened at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback